Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A4 | P14672 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | NOS3 | P29474 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gapicomine SCHEMBL1037773 | 0.92 | SLC2A4 (0.61) | SLC2A4GAANOS3NOS2CYP2D6 | |
| Gapicomine SCHEMBL9336954 | 0.90 | SLC2A4 (0.59) | SLC2A4GAACYP2D6CYP1A2SMN1; SMN2 | |
| Gapicomine SCHEMBL6121683 | 0.90 | SLC2A4 (0.59) | SLC2A4GAACYP2D6CYP1A2SMN1; SMN2 | |
| SCHEMBL10054983 | 0.90 | SLC2A4 (0.59) | SLC2A4GAACYP2D6CYP1A2SMN1; SMN2 | |
| SCHEMBL1042566 | 0.83 | SLC2A4 (0.63) | SLC2A4GAACYP2D6CYP1A2SMN1; SMN2 | |
| SCHEMBL29444840 | 0.82 | MEN1 (0.56) | SLC2A4GAACYP2D6SMN1; SMN2TDP1 | |
| SCHEMBL3238227 | 0.79 | SLC2A4 (0.50) | SLC2A4GAACYP2D6CYP1A2SMN1; SMN2 | |
| SCHEMBL2236862 | 0.79 | LOXL2 (0.70) | SLC2A4GAANOS3NOS2SMN1; SMN2 | |
| SCHEMBL1042452 | 0.79 | SLC2A4 (0.50) | SLC2A4GAANOS3NOS2CYP2D6 | |
| SCHEMBL20847619 | 0.79 | SMN1; SMN2 (0.56) | SLC2A4GAASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | RAN, RANBP1, GDI2 | SLC2A4 2275/4885GAA 336/4885NOS3 3655/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | SLC2A4 2275/4885GAA 336/4885NOS3 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.